Switzerland-based pharmaceutical company Novartis announced Tuesday that it has lost its appeal of a competition fine issued by Italian officials for anticompetitive conduct.
According to reports, a regional court in Italy upheld fines issued to Novartis and its rival Roche for anticompetitive conduct; the nation’s Competition Authority sanctioned the companies last March after finding the firms had colluded to prevent market entry of a cancer drug for use as an eye disease treatment. The companies were fined $226 million, reports say.
While the fines were upheld, Novartis still denies the decision. “Novartis firmly rejects the accusations of anticompetitive practices and any allegations of anticompetitive behavior are unfounded and without merit,” the company said in a statement, adding that the company will appeal this decision as well.
Full content: Reuters
Want more news? Subscribe to CPI’s free daily newsletter for more headlines and updates on antitrust developments around the world.
Featured News
T-Mobile Faces Class-Action Lawsuit Over Sprint Merger After Appeal Denied
May 16, 2024 by
CPI
Google Faces Backlash Over Introduction of AI-Generated Summaries in Searches
May 16, 2024 by
CPI
CMA Launches Phase 2 Probe into AlphaTheta’s Acquisition of Serato
May 16, 2024 by
CPI
NFL Executive Escapes Testifying in High-Stakes Trial Over Televised Games
May 16, 2024 by
CPI
EU Consumers Lodge Complaint Against Chinese Retailer Temu Over Content Rules Breach
May 16, 2024 by
CPI
Antitrust Mix by CPI
Antitrust Chronicle® – Ecosystems
May 9, 2024 by
CPI
Mapping Antitrust onto Digital Ecosystems
May 9, 2024 by
CPI
Ecosystems and Competition Law: A Law and Political Economy Approach
May 9, 2024 by
CPI
Ecosystem Theories of Harm: What is Beyond the Buzzword?
May 9, 2024 by
CPI
Open Ecosystems: Benefits, Challenges, and Implications for Antitrust
May 9, 2024 by
CPI